Experimental Therapeutics Program

实验治疗计划

基本信息

批准号：
10267041
负责人：
MARIA R BAER
金额：
$ 4.9万
依托单位：
UNIVERSITY OF MARYLAND BALTIMORE
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-08-08 至 2026-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10267041
关键词：
Address Advisory Committees Baltimore Basic Science Biometry Cancer Center Catchment Area Cigarette Clinic Clinical Clinical Investigator Collaborations Community Outreach Comprehensive Cancer Center County Detection Development Diagnosis Diagnostic Direct Costs Doctor of Medicine Doctor of Philosophy Early Diagnosis Faculty Flow Cytometry Funding Funding Agency Genomics Goals Grant Hematologic Neoplasms Human Image In Vitro Industry Institutes Investigational Therapies Journals Laboratories Laboratory Study Leadership Malignant Neoplasms Maryland Measurement Medical Medical center Mission Molecular Molecular Biology Molecular Target NCI Center for Cancer Research Nanotechnology Pathology Patient-Focused Outcomes Peer Review Pharmacy Schools Population Sciences Positioning Attribute Preclinical Testing Public Health Schools Publications Radiation Oncology Radiation Protection Radiation therapy Research Research Personnel Research Priority School Dentistry Services Solid Neoplasm Source Suggestion System Testing Therapeutic Translating Treatment outcome Universities acronyms anticancer research base biobank cancer therapy college community engagement early phase clinical trial hormone related cancer improved in vivo innovation liquid biopsy medical schools member molecular carrier neoplasm immunotherapy new technology novel novel therapeutic intervention novel therapeutics pre-clinical pre-clinical research professor programs recruit research clinical testing response structural biology translational scientist tumor immunology virology

项目摘要

10.0 Abstract: Experimental Therapeutics (ET) Program The overarching goal of ET is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to evaluate their findings in clinical settings. To achieve this mission, the program focuses on three specific aims: Aim 1: Target detection and measurement—Investigate diagnostic advances, including molecular early detection, liquid biopsy and imaging, to guide new treatment approaches and assessments of response; Aim 2: Molecular targeting: Development and preclinical and clinical testing—Investigate new cancer therapies based on novel molecular targets in in vitro and in vivo laboratory studies as well as early phase clinical trials; and Aim 3: Treatment delivery: Novel delivery strategies—Investigate the development of new technologies for therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy and radiation protection approaches. To achieve these three aims, members of ET are supported by extensive expertise available in other University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) Programs to translate basic research findings to the clinic and by the availability of exceptional shared services. The ET Program has 56 members, including 31 full members and 25 associate members, who conduct cancer-focused research that receives $14.6 million direct cost annual funding ($19.4 million total), including $3.6 million (25%) from NCI and $4.1 million from other peer-reviewed sources. ET Program members receive $6.9 million annually from non-peer-reviewed funding sources. During this funding period, ET members authored 889 cancer-related publications, of which 22% resulted from intraprogrammatic, 21% from interprogrammatic, and 8% from intra- and interprogrammatic collaborations. Of the 889 publications, 72% include collaborations with external investigators, reflecting the high national impact of the ET Program. A high percentage of ET publications (14%) were in journals with an impact factor ≥10. Research efforts of ET members are supported by extensive use of all shared services. The ET Program collaborates with the other four UMGCCC research programs and facilitate community outreach and engagement (COE) to identify and address the cancer research priorities of the catchment area.

10.0 摘要：实验治疗（ET）计划 ET 的首要目标是开发和测试实体瘤和血液恶性肿瘤的新疗法基于创新的临床前研究，重点是从 ET 中获得基础和临床前发现。成员参与早期临床测试，并为其他项目的研究人员提供平台为了实现这一使命，该计划重点关注三个具体目标：目标 1：目标检测和测量——研究诊断进展，包括分子早期诊断检测、液体活检和成像，以指导新的治疗方法和疗效评估；分子靶向：开发、临床前和临床测试——研究新的癌症疗法基于体外和体内实验室研究以及早期临床试验的新分子靶标；目标 3：治疗实施：新颖的实施策略——研究新技术的开发用于治疗传递，包括分子载体、纳米技术以及新型放射治疗和放射治疗为了实现这三个目标，ET 成员得到了广泛的专业知识的支持。其他马里兰大学 Marlene 和 Stewart Greenebaum 综合癌症中心提供 (UMGCCC) 将基础研究成果转化为临床的计划，并通过提供特殊的 ET 计划有 56 名成员，其中正式成员 31 名，准成员 25 名。开展以癌症为重点的研究，每年获得 1,460 万美元的直接费用资助（总计 1,940 万美元），其中包括来自 NCI 的 360 万美元（25%）和来自其他同行评审来源的 410 万美元。在此资助期间，ET 成员每年从非同行评审资金来源获得 690 万美元。撰写了 889 篇癌症相关出版物，其中 22% 来自程序内，21% 来自项目间合作，8% 来自项目内和项目间合作在 889 份出版物中，72% 来自项目内和项目间合作。包括与外部研究人员的合作，反映了 ET 计划的高度国家影响力。 ET 成员研究成果发表在影响因子≥10 的期刊上的百分比 (14%)。通过广泛使用所有共享服务来支持 ET 计划与其他四个 UMGCCC 合作。研究计划并促进社区外展和参与 (COE)，以识别和解决癌症集水区的研究重点。